This is a StreetInsider.com Premium Only Page

Antares Pharma (ATRS) – Company Press Releases

May 2, 2023 09:00 AM Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

May 12, 2022 08:00 AM Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

Apr 26, 2022 08:00 AM HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

Apr 13, 2022 01:55 PM ANTARES PHARMA ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ATRS and Encourages Investors to Contact the Firm

Apr 13, 2022 06:00 AM Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader

Mar 29, 2022 07:00 AM Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy

Mar 3, 2022 07:00 AM Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results

Feb 28, 2022 08:30 AM Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference

Feb 17, 2022 08:30 AM Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

Feb 3, 2022 08:00 AM Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®

Jan 18, 2022 07:30 AM Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue

Jan 12, 2022 08:30 AM Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources

Jan 11, 2022 07:30 AM Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue

Dec 17, 2021 07:53 AM MedMira strengthen its Board with New Appointment

Dec 15, 2021 05:58 PM Antares Pharma Announces Divestiture of Otrexup®

Nov 22, 2021 08:00 AM Antares Pharma to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Nov 10, 2021 08:30 AM Antares Pharma to Present at the Jefferies London Healthcare Conference

Nov 4, 2021 07:00 AM Antares Pharma Reports Third Quarter 2021 Financial and Operating Results

Oct 28, 2021 08:00 AM Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors

Oct 25, 2021 08:30 AM Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNA

Oct 21, 2021 08:30 AM Antares Pharma to Report Third Quarter 2021 Financial and Operating Results

Oct 18, 2021 07:00 AM Antares Pharma Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S.

Sep 30, 2021 09:00 AM Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue

Sep 8, 2021 08:30 AM Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Aug 5, 2021 07:00 AM Antares Pharma Reports Second Quarter 2021 Financial and Operating Results

Jul 28, 2021 08:30 AM Antares Pharma to Report Second Quarter 2021 Financial and Operating Results

Jul 22, 2021 08:30 AM Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for Adrenal Crisis Rescue

Jul 7, 2021 08:30 AM Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Conference

Jun 28, 2021 08:30 AM Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction

Jun 28, 2021 01:00 AM Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

Jun 22, 2021 09:00 AM Antares Pharma Announces Submission of IND Application for ATRS-1902 for Adrenal Crisis Rescue

Jun 15, 2021 08:30 AM Antares Pharma to Present at the Raymond James Human Health Innovations Conference

May 26, 2021 08:30 AM Antares Pharma to Present at the Jefferies Virtual Healthcare Conference

May 6, 2021 07:15 AM Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial

May 6, 2021 07:00 AM Antares Pharma Reports First Quarter 2021 Financial and Operating Results

May 3, 2021 08:30 AM Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting

Apr 28, 2021 08:30 AM Antares Pharma to Participate in the 7th Annual Truist Securities 2021 Life Sciences Summit

Apr 27, 2021 08:30 AM Antares Pharma to Report First Quarter 2021 Financial and Operating Results

Apr 26, 2021 08:30 AM Antares Pharma Appoints Dr. Peter Richardson as Executive Vice President, Research and Development and Chief Medical Officer

Mar 2, 2021 07:00 AM Antares Pharma Reports Fourth Quarter and Full-Year 2020 Financial and Operating Results

Feb 24, 2021 04:30 PM Antares Pharma to Present at Two Upcoming Investor Conferences

Feb 23, 2021 08:30 AM Antares Pharma to Report Fourth Quarter and Full-Year 2020 Financial and Operating Results

Feb 17, 2021 08:30 AM Antares Pharma to Participate in the SVB Leerink 10th Annual Virtual Global Healthcare Conference

Jan 11, 2021 08:00 AM Antares Pharma Announces Full-Year 2021 Revenue Guidance of $175-200 Million

Nov 23, 2020 04:05 PM Antares Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Nov 10, 2020 04:30 PM Antares Pharma to Present at the Jefferies Virtual London Healthcare Conference

Nov 5, 2020 07:00 AM Antares Pharma Reports Strong Third Quarter 2020 Financial and Operating Results

Oct 22, 2020 08:30 AM Antares Pharma to Report Third Quarter 2020 Financial and Operating Results

Oct 1, 2020 08:46 AM Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.

Sep 8, 2020 08:00 AM Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference